118 related articles for article (PubMed ID: 37989009)
21. Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study.
Vaccarella S; Franceschi S; Zaridze D; Poljak M; Veerus P; Plummer M; Bray F
Lancet Oncol; 2016 Oct; 17(10):1445-1452. PubMed ID: 27567054
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
23. A retrospective analysis of human papillomavirus (HPV) prevalence and genotype distribution among 25,238 women in Shanghai, China revealed the limitations of current HPV-based screening and HPV vaccine.
Ruan Y; Li H; Liu M; Cao G; Xu X; Han L; Li F
Cancer Epidemiol; 2023 Jun; 84():102372. PubMed ID: 37119603
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up on HIV infected and non-infected women with cervical cancer from Tanzania: staging, access to cancer-directed therapies and associated survival in a real-life remote setting.
Glasmeyer L; Mcharo RD; Torres L; Lennemann T; Danstan E; Mwinuka N; Judick M; Mueller W; Mbuya W; Hölscher M; Lellé R; Geldmacher C; Kroidl A; France JR
BMC Cancer; 2022 Aug; 22(1):892. PubMed ID: 35971100
[TBL] [Abstract][Full Text] [Related]
25. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
26. Cervical cancer screening history among women diagnosed with cervical cancer in Estonia 2017-18.
Orumaa M; Innos K; Suurna M; Veerus P
Eur J Public Health; 2023 Feb; 33(1):64-68. PubMed ID: 36469798
[TBL] [Abstract][Full Text] [Related]
27. Childhood cancer incidence and survival trends in Estonia (1970-2016): a nationwide population-based study.
Paapsi K; Baburin A; Mikkel S; Mägi M; Saks K; Innos K
BMC Cancer; 2020 Jan; 20(1):30. PubMed ID: 31924184
[TBL] [Abstract][Full Text] [Related]
28. Temporal changes in the cervical cancer burden in Bulgaria: Implications for eastern european countries going through transition.
Samson KK; Haynatzki G; Soliman AS; Valerianova Z
Cancer Epidemiol; 2016 Oct; 44():154-160. PubMed ID: 27597149
[TBL] [Abstract][Full Text] [Related]
29. Cervical cancer sociodemographic and diagnostic disparities in Florida: a population-based study (1981-2013) by stage at presentation.
Gauri A; Messiah SE; Bouzoubaa LA; Moore KJ; Koru-Sengul T
Ethn Health; 2020 Oct; 25(7):995-1003. PubMed ID: 29732918
[No Abstract] [Full Text] [Related]
30. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
Syrjänen K
Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
[TBL] [Abstract][Full Text] [Related]
31. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
[TBL] [Abstract][Full Text] [Related]
32. Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California.
Cooley JJP; Maguire FB; Morris CR; Parikh-Patel A; Abrahão R; Chen HA; Keegan THM
Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):91-97. PubMed ID: 36620897
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
Wheeler CM; Hunt WC; Joste NE; Key CR; Quint WG; Castle PE
J Natl Cancer Inst; 2009 Apr; 101(7):475-87. PubMed ID: 19318628
[TBL] [Abstract][Full Text] [Related]
34. [Cervical cancer: Current situation and management in Morocco].
Belglaiaa E; Mougin C
Bull Cancer; 2019 Nov; 106(11):1008-1022. PubMed ID: 31606139
[TBL] [Abstract][Full Text] [Related]
35. Trends in cervical cancer incidence and mortality in Bulgaria, Estonia, Latvia, Lithuania and Romania.
Arbyn M; Antoine J; Valerianova Z; Mägi M; Stengrevics A; Smailyte G; Suteu O; Micheli A
Tumori; 2010; 96(4):517-23. PubMed ID: 20968129
[TBL] [Abstract][Full Text] [Related]
36. Sex differences in cancer survival in Estonia: a population-based study.
Innos K; Padrik P; Valvere V; Aareleid T
BMC Cancer; 2015 Feb; 15():72. PubMed ID: 25886269
[TBL] [Abstract][Full Text] [Related]
37. Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades.
Ojamaa K; Veerus P; Baburin A; Everaus H; Innos K
Cancer Epidemiol; 2019 Oct; 62():101566. PubMed ID: 31326850
[TBL] [Abstract][Full Text] [Related]
38. Quality Assessment of Cervical Cytology Practices in Estonia From 2007 to 2018.
Orumaa M; Innos K; Suurna M; Salumäe L; Veerus P
Cancer Control; 2022; 29():10732748221141794. PubMed ID: 36542780
[TBL] [Abstract][Full Text] [Related]
39. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system.
Chao C; Silverberg MJ; Becerra TA; Corley DA; Jensen CD; Chen Q; Quinn VP
Am J Obstet Gynecol; 2017 Feb; 216(2):151.e1-151.e9. PubMed ID: 27746152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
